Lexicon expects delay in FDA feedback on additional data for its diabetes drug
(Reuters) -Lexicon Pharmaceuticals said on Monday the U.S. Food and Drug Administration requires more time to review the company’s previously submitted additional data on its experimental drug, zynquista, for patients with type 1 diabetes. The health regulator now expects to provide feedback in the fourth quarter, delaying its initial timeline set for the end of …
Lexicon expects delay in FDA feedback on additional data for its diabetes drug Read More »










